New vaccine tested to stop deadly cervical Cancer's return
NCT ID NCT02405221
Summary
This early-stage study tested the safety of a vaccine called TA-CIN in patients who had recently finished treatment for HPV16 cervical cancer and were currently cancer-free. The goal was to see if the vaccine could safely trigger an immune response to help prevent the cancer from coming back. Researchers gave the vaccine to 15 participants and monitored them for side effects and immune system reactions.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HPV16 ASSOCIATED CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, 21287, United States
-
Women & Infants Center, University of Alabama at Birmingham
Birmingham, Alabama, 35233, United States
Conditions
Explore the condition pages connected to this study.